Last reviewed · How we verify
Intralesional administration of 5-fluorouracil
Intralesional administration of 5-fluorouracil is a Small molecule drug developed by Instituto de Oftalmología Fundación Conde de Valenciana. It is currently FDA-approved.
At a glance
| Generic name | Intralesional administration of 5-fluorouracil |
|---|---|
| Sponsor | Instituto de Oftalmología Fundación Conde de Valenciana |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Application of Intralesional 5-fluorouracil for the Management of Hypertrophic Facial Scars in the Periocular Region Resulting From Trauma and Surgical Procedures in Individuals Aged Over 18 Years (PHASE4)
- The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial. (NA)
- Efficacy and Safety of Intralesional 5-Fluorouracil and Triamcinolone Acetonide in Keloids and Hypertrophic Scars
- Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC (PHASE1)
- A Randomized, Double-blinded, Self-controlled Clinical Study of Intralesional Injection of 5-fluorouracil Plus Triamcinolone for the Treatment of Refractory Nodular Prurigo (PHASE3)
- The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma (PHASE3)
- Keloid Scarring: Treatment and Pathophysiology (PHASE4)
- Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intralesional administration of 5-fluorouracil CI brief — competitive landscape report
- Intralesional administration of 5-fluorouracil updates RSS · CI watch RSS
- Instituto de Oftalmología Fundación Conde de Valenciana portfolio CI
Frequently asked questions about Intralesional administration of 5-fluorouracil
What is Intralesional administration of 5-fluorouracil?
Intralesional administration of 5-fluorouracil is a Small molecule drug developed by Instituto de Oftalmología Fundación Conde de Valenciana.
Who makes Intralesional administration of 5-fluorouracil?
Intralesional administration of 5-fluorouracil is developed and marketed by Instituto de Oftalmología Fundación Conde de Valenciana (see full Instituto de Oftalmología Fundación Conde de Valenciana pipeline at /company/instituto-de-oftalmolog-a-fundaci-n-conde-de-valenciana).
What development phase is Intralesional administration of 5-fluorouracil in?
Intralesional administration of 5-fluorouracil is FDA-approved (marketed).